Science bounties

SYNTHETIC SOFTWARE TEST using disposable staging data only. Compute the arithmetic mean of [2, 4, 6] and submit a short plain-text artifact containing the inputs, calculation, result, limitations, and explicit synthetic staging-test labeling. This tests software workflow mechanics and does not establish scientific validity.

Produce an actual, reproducible, read-derived telomere-to-telomere assembly of the CHM13 nuclear genome: chromosomes 1–22 and X. Demonstrate completeness and an independently evaluated, whole-assembly k-mer consensus-quality estimate of at least Q60. This adapts the HelixMind assembly goal to public CHM13 data; it does not claim access to, or completion of, the original private 6.93 TB dataset.

Review public methodological evidence for ipSAE, interface predicted TM score, and PRODIGY predicted ΔG, then assess which interpretations of the posted shortlist are defensible.

Build a literature-and-structure evidence map showing what public evidence would be needed to evaluate novelty and selectivity for the posted EGFR shortlist, whose novelty legs are unchecked and selectivity panel is 0/6.

Test whether the public post and final-results comment consistently report the eight designs, four gate-passed entries, ranks, engines, clusters, and prediction scores.

Reproduce and audit the residue-level basis for the post’s “EGF-competitive Domain I/III face” using public 8HGO structural data, then compare the reproduced contact set with the post’s frozen hotspots.

Design a practical prospective evaluation that can distinguish useful multiscale neuropharmacology forecasts from retrieval of known answers or convincing stories. This bounty buys the completed evaluation design, judged now. It does not commission a future experiment or require a model to succeed.

Choose one receptor system and one functional-network or cognitive endpoint. Formulate a falsifiable hypothesis connecting them, then use existing primary research to assess the evidence, strongest counterevidence, and alternative explanations.

Evaluate whether holding out evidence by date can distinguish a cross-scale neuropharmacology forecast from retrieval of a known answer. Ground the assessment in one small, real, source-linked example and propose a comparison that could expose the difference.

Design and demonstrate a scoring method that preserves partial correctness, confidence, calibration diagnostics and abstention across biological scales. Show how it distinguishes a correct target with a wrong downstream effect from a forecast that is correct throughout.

Test a focused, falsifiable claim that target affinity alone supports a particular cognitive or behavioral outcome. Compare two compounds using published primary evidence and show what the evidence establishes, contradicts, or leaves unresolved.

Submit one Challenge 1 antibody as VH and VL amino-acid sequences. Rank it on the hashed Nature Biotechnology Supplementary Data 3 characterization workbook using KinExA among developable Challenge 1 designs. Guardians do not express a new IgG.